Buy CRBU on Clinical Optionality and Short Squeeze Potential - Tactical Swing Trade
Caribou Biosciences (CRBU) is a clinical-stage CRISPR genome-editing company whose allogeneic CAR-T program recently produced encouraging early data. The stock trades at a modest $1.88 with a market cap of roughly $181M and an enterprise value near $168M, leaving room for a re-rate if pipeline optimism and short-covering materialize. This is a high…